Compare TSCO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSCO | BIIB |
|---|---|---|
| Founded | 1938 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0B | 24.2B |
| IPO Year | 1994 | 1991 |
| Metric | TSCO | BIIB |
|---|---|---|
| Price | $54.03 | $171.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 23 |
| Target Price | $63.00 | ★ $179.48 |
| AVG Volume (30 Days) | ★ 6.7M | 1.4M |
| Earning Date | 01-29-2026 | 02-06-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ 0.57 | N/A |
| EPS | 2.07 | ★ 10.97 |
| Revenue | ★ $15,399,257,000.00 | $10,065,900,000.00 |
| Revenue This Year | $7.29 | $3.56 |
| Revenue Next Year | $6.51 | N/A |
| P/E Ratio | $25.81 | ★ $15.84 |
| Revenue Growth | 4.26 | ★ 4.77 |
| 52 Week Low | $46.85 | $110.04 |
| 52 Week High | $63.99 | $190.20 |
| Indicator | TSCO | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 61.66 | 45.71 |
| Support Level | $50.18 | $160.36 |
| Resistance Level | $51.98 | $175.29 |
| Average True Range (ATR) | 1.37 | 6.18 |
| MACD | 0.45 | -1.26 |
| Stochastic Oscillator | 81.82 | 35.48 |
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,364 of its namesake banners in 49 states, along with 206 Petsense by Tractor Supply stores. Stores are generally concentrated in rural communities rather than urban and suburban areas. In fiscal 2024, revenue consisted primarily of livestock, equine & agriculture (26%), companion animal (25%), and seasonal & recreation (23%).
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).